# Sandro Pignata

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/sandro-pignata/

## Facts

| Field | Value |
| --- | --- |
| Citations | 36,516 |
| Field | Ovarian cancer diagnosis and treatment |
| h-index | 81 |
| i10-index | 367 |
| Last Known Institution | Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" |
| OpenAlex ID | https://openalex.org/A5083659627 |
| ORCID iD | https://orcid.org/0000-0002-8836-2633 |
| Works | 897 |

## Researcher papers

Showing 12 of 17.

- [Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer](https://scholariq.org/papers/olaparib-plus-bevacizumab-as-first-line-maintenance-in-ovarian-cancer/)
- [Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial](https://scholariq.org/papers/olaparib-tablets-as-maintenance-therapy-in-patients-with-platinum-sensitive/)
- [Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/rucaparib-maintenance-treatment-for-recurrent-ovarian-carcinoma-after-response/)
- [ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease](https://scholariq.org/papers/esmo-esgo-consensus-conference-recommendations-on-ovarian-cancer-pathology-and/)
- [The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients With Cervical Cancer](https://scholariq.org/papers/the-european-society-of-gynaecological-oncology-european-society-for-3/)
- [Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer](https://scholariq.org/papers/mirvetuximab-soravtansine-in-fr-positive-platinum-resistant-ovarian-cancer/)
- [Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study](https://scholariq.org/papers/efficacy-and-safety-of-tisotumab-vedotin-in-previously-treated-recurrent-or/)
- [The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancer](https://scholariq.org/papers/the-european-society-of-gynaecological-oncology-european-society-for-2/)
- [Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study](https://scholariq.org/papers/efficacy-and-safety-of-mirvetuximab-soravtansine-in-patients-with-platinum/)
- [The forefront of ovarian cancer therapy: update on PARP inhibitors](https://scholariq.org/papers/the-forefront-of-ovarian-cancer-therapy-update-on-parp-inhibitors/)
- [Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial](https://scholariq.org/papers/pembrolizumab-or-placebo-with-chemoradiotherapy-followed-by-pembrolizumab-or/)
- [Treatment of recurrent ovarian cancer](https://scholariq.org/papers/treatment-of-recurrent-ovarian-cancer/)

## Researcher topics

- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Endometrial and Cervical Cancer Treatments](https://scholariq.org/topics/endometrial-and-cervical-cancer-treatments/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [BRCA gene mutations in cancer](https://scholariq.org/topics/brca-gene-mutations-in-cancer/)

## Researcher university

- [Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"](https://scholariq.org/institutions/istituto-nazionale-tumori-irccs-fondazione-g-pascale/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.